Abbott Laboratories (ABT)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 7,616,000 | 7,558,000 | 6,987,000 | 6,284,000 | 6,896,000 | 6,709,000 | 7,835,000 | 9,882,000 | 9,882,000 | 9,594,000 | 8,937,000 | 7,675,000 | 9,799,000 | 9,302,000 | 8,658,000 | 8,054,000 | 6,838,000 | 4,480,000 | 4,763,000 | 3,377,000 |
| Short-term investments | US$ in thousands | 351,000 | 230,000 | 232,000 | 367,000 | 383,000 | 338,000 | 320,000 | 288,000 | 288,000 | 313,000 | 353,000 | 483,000 | 450,000 | 390,000 | 286,000 | 318,000 | 310,000 | 251,000 | 274,000 | 291,000 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 14,157,000 | 14,902,000 | 13,760,000 | 14,021,000 | 13,841,000 | 13,042,000 | 14,350,000 | 15,489,000 | 15,489,000 | 13,365,000 | 12,392,000 | 12,647,000 | 13,105,000 | 12,867,000 | 12,614,000 | 12,462,000 | 11,907,000 | 10,257,000 | 10,959,000 | 10,808,000 |
| Quick ratio | 0.56 | 0.52 | 0.52 | 0.47 | 0.53 | 0.54 | 0.57 | 0.66 | 0.66 | 0.74 | 0.75 | 0.65 | 0.78 | 0.75 | 0.71 | 0.67 | 0.60 | 0.46 | 0.46 | 0.34 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($7,616,000K
+ $351,000K
+ $—K)
÷ $14,157,000K
= 0.56
The quick ratio of Abbott Laboratories, which measures the company's ability to meet its short-term obligations with its most liquid assets, has shown some fluctuation over the reported periods. The quick ratio increased from 0.34 as of March 31, 2020, to 0.78 as of December 31, 2021, indicating an improved ability to cover its current liabilities with quick assets.
However, there was a slight decrease in the quick ratio to 0.47 as of March 31, 2024. It is important to note that a quick ratio above 1 indicates that a company has enough liquid assets to cover its short-term liabilities, while a ratio below 1 may signal potential liquidity issues. Abbott Laboratories' quick ratio has generally remained above 0.5, suggesting a reasonable level of liquidity to meet its short-term obligations.
Peer comparison
Dec 31, 2024